Introduction:Basic information about CAS 7261-97-4|Dantrolene, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Dantrolene |
|---|
| CAS Number | 7261-97-4 | Molecular Weight | 314.25300 |
|---|
| Density | 1.57 g/cm3 | Boiling Point | 175-177ºC |
|---|
| Molecular Formula | C14H10N4O5 | Melting Point | 279-280°C (lit.) |
|---|
| MSDS | / | Flash Point | / |
|---|
Names
| Name | dantrolene |
|---|
| Synonym | More Synonyms |
|---|
Dantrolene BiologicalActivity
| Description | Dantrolene (F368), a muscle relaxant, non-competitively inhibits human erythrocyte glutathione reductase. Ki and IC50 values are 111.6 μM and 52.3 μM, respectively. Dantrolene is a ryanodine receptor antagonist and Ca2+ signaling stabilizer. Dantrolene can be used for the research of muscle spasticity, malignant hyperthermia, Huntington's disease and other neuroleptic malignant syndrome[1][2][3][4][5]. |
|---|
| Related Catalog | Signaling Pathways >>Others >>OthersResearch Areas >>Inflammation/ImmunologyResearch Areas >>Neurological Disease |
|---|
| In Vitro | Dantrolene interferes with calcium release from the sarcoplasmic reticulum and thus to inhibit excitation--contraction coupling[1]. Dantrolene acts directly on the RYR1 to reduce the extent of channel activation by calmodulin (CaM) and thereby decreases the Ca2+ sensitivity of channel activation[2]. Dantrolene inhibits abnormal Ca2+ release from the sarcoplasmic reticulum[3]. Dantrolene depresses excitation-contraction coupling in muscle fibers by inhibiting calcium release from the sarcoplasmic reticulum[3]. Dantrolene also shows calcium channel blocker effect in the smooth muscle membrane as well as antioxidative and cytoprotective properties[3]. Dantrolene affects the membrane calcium channel of smooth muscle cells and inhibits calcium influx[3]. Dantrolene is a skeletal muscle-specific muscle relaxant that works on the cardiac muscle. Dantrolene (0.3 μM) binds to domain 601-620 of RyR2 and corrects defective inter-domain interaction within RyR2 in failing hearts. This in turn inhibits spontaneous Ca2++ leak/Ca2+ sparks, and improves cardiomyocyte function in failing hearts[4]. |
|---|
| In Vivo | Dantrolene is neuroprotective in Huntington's disease transgenic mouse model[5]. Feeding dantrolene (5 mg/kg) twice a week to YAC128 mice between 2 months and 11.5 months of age resulted in significantly improved performance in the beam-walking and gait-walking assays[5]. Animal Model: YAC128 transgenic mice (FVBN/NJ background strain) and WT mice[5] Dosage: 5 mg/kg Administration: Fed orally twice per week from 2 to 11.5 months of age, followed by a washout period of 2 months (13.5 months of age) Result: Resulted in significantly improved performance in the beam-walking and gait-walking assays. |
|---|
| References | [1]. W J Meyler, et al. The effect of dantrolene sodium on rat skeletal muscle in relation to the plasma concentration. Eur J Pharmacol. 1979 Feb 1;53(4):335-42. [2]. F Zhao, et al. Dantrolene inhibition of ryanodine receptor Ca2+ release channels. Molecular mechanism and isoform selectivity. J Biol Chem. 2001 Apr 27;276(17):13810-6. [3]. Murat Sentürk, et al. Dantrolene inhibits human erythrocyte glutathione reductase. Biol Pharm Bull. 2008 Nov;31(11):2036-9. [4]. Shigeki Kobayashi, et al. Dantrolene, a therapeutic agent for malignant hyperthermia, markedly improves the function of failing cardiomyocytes by stabilizing interdomain interactions within the ryanodine receptor. J Am Coll Cardiol. 2009 May 26;53(21):1993-2005. [5]. Xi Chen, et al. Dantrolene is neuroprotective in Huntington's disease transgenic mouse model. Mol Neurodegener. 2011 Nov 25;6:81. |
|---|
Chemical & Physical Properties
| Density | 1.57 g/cm3 |
|---|
| Boiling Point | 175-177ºC |
|---|
| Melting Point | 279-280°C (lit.) |
|---|
| Molecular Formula | C14H10N4O5 |
|---|
| Molecular Weight | 314.25300 |
|---|
| Exact Mass | 314.06500 |
|---|
| PSA | 120.73000 |
|---|
| LogP | 2.53040 |
|---|
| Index of Refraction | 1.715 |
|---|
| InChIKey | OZOMQRBLCMDCEG-UHFFFAOYSA-N |
|---|
| SMILES | O=C1CN(N=Cc2ccc(-c3ccc([N+](=O)[O-])cc3)o2)C(=O)N1 |
|---|
Toxicological Information
CHEMICAL IDENTIFICATION - RTECS NUMBER :
- MU3874000
- CHEMICAL NAME :
- Hydantoin, 1-((5-(p-nitrophenyl)furfurylidene)amino)-
- CAS REGISTRY NUMBER :
- 7261-97-4
- BEILSTEIN REFERENCE NO. :
- 0705189
- LAST UPDATED :
- 199612
- DATA ITEMS CITED :
- 2
- MOLECULAR FORMULA :
- C14-H10-N4-O5
- MOLECULAR WEIGHT :
- 314.28
HEALTH HAZARD DATAACUTE TOXICITY DATA - TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- >7 gm/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- JMCMAR Journal of Medicinal Chemistry. (American Chemical Soc., Distribution Office Dept. 223, POB POB 57136, West End Stn., Washington, DC 20037) V.6- 1963- Volume(issue)/page/year: 21,127,1978 ** TUMORIGENIC DATA **
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Unreported
- SPECIES OBSERVED :
- Human - man
- DOSE/DURATION :
- 9386 mg/kg/3Y-C
- TOXIC EFFECTS :
- Tumorigenic - Carcinogenic by RTECS criteria Blood - lymphoma, including Hodgkin's disease
- REFERENCE :
- PGMJAO Postgraduate Medical Journal. (Blackwell Scientific Pub. Ltd., POB 88, Oxford, UK) V.1- 1925- Volume(issue)/page/year: 56,261,1980
|
Safety Information
| Hazard Codes | Xi |
|---|
| RIDADR | NONH for all modes of transport |
|---|
Synonyms
| Dantrium |
| 1-[5-(4-nitro-phenyl)-furan-2-ylmethyleneamino]-imidazolidine-2,4-dione |
| 1-[(E)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione |
| Dantroleno [INN-Spanish] |
| Dantrolenum [INN-Latin] |
| UNII-F64QU97QCR |
| danthrolene |
| Dantrium Intravenous |
| Dantrolenum |
| 1-[((5-(4-nitrophenyl)-2-furanyl)methylene)amino]-2,4-imidazolidinedione |
| Dantroleno |